Possible "costs" and "savings" to the provinces of Bill C-22.: RG47-19/1986E-PDF
"Bill C-22 provides for a transitional phase-in of the periods of market exclusivity. Because provincial governments have been expecting a number of generic drugs to be on the market sooner than the Bill provides for, there will be transitional adjustment assistance to the provincial governments of $100 million over 4 years. This note derives the possible "cost" estimate based on a "worst case scenario" basis. In addition, it reports the possible savings to consumers due to the presence of the Drug Prices Review Board"--Introduction.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.883873&sl=0
| Department/Agency | Canada. Consumer and Corporate Affairs Canada, issuing body. |
|---|---|
| Title | Possible "costs" and "savings" to the provinces of Bill C-22. |
| Publication type | Monograph |
| Language | [English] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Digitized edition from print [produced by Innovation, Science and Economic Development Canada]. |
| Publishing information | [Ottawa] : Consumer and Corporate Affairs Canada, Bureau of Policy Coordination = Consommation et corporations Canada, Bureau de la coordination des politiques, [1986] |
| Description | 1 online resource (5 pages) |
| Catalogue number |
|
| Subject terms | Canada. Patent Act. Drugs -- Prices -- Canada. Patent licenses -- Canada. Médicaments -- Prix -- Canada. Licences de brevets -- Canada. |